Cargando…

Peripheral Latanoprost Administration Lowers Intraocular Pressure in the Wistar Rat

PURPOSE: Instillation of latanoprost eye drops into the conjunctival sac to lower intraocular pressure (IOP) is the most frequently used treatment for primary open-angle glaucoma. The aim of this study was to evaluate the influence of latanoprost on IOP in the rat when applied peripherally. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Świątkiewicz, Maciej, Wełniak-Kamińska, Marlena, Fiedorowicz, Michał, Kamińska, Agnieszka, Rejdak, Robert, Grieb, Paweł
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406633/ https://www.ncbi.nlm.nih.gov/pubmed/32383108 http://dx.doi.org/10.1007/s40123-020-00256-8

Ejemplares similares

Increases in Brain (1)H-MR Glutamine and Glutamate Signals Following Acute Exhaustive Endurance Exercise in the Rat
por: Świątkiewicz, Maciej, et al.
Publicado: (2017)

Changes of Ocular Dimensions as a Marker of Disease Progression in a Murine Model of Pigmentary Glaucoma
por: Fiedorowicz, Michał, et al.
Publicado: (2020)

Citicoline: A Candidate for Adjunct Treatment of Multiple Sclerosis
por: Grieb, Paweł, et al.
Publicado: (2021)

Tryptophan Pathway Abnormalities in a Murine Model of Hereditary Glaucoma
por: Fiedorowicz, Michal, et al.
Publicado: (2021)

Volumes of brain structures in captive wild-type and laboratory rats: 7T magnetic resonance in vivo automatic atlas-based study
por: Welniak–Kaminska, Marlena, et al.
Publicado: (2019)

TP53-Deficient Angiosarcoma Expression Profiling in Rat Model
por: Smyczyńska, Urszula, et al.
Publicado: (2020)

Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis
por: Lee, Jong-Wook, et al.
Publicado: (2022)

Intraocular Pressure-Lowering Effect of Latanoprost Is Hampered by Defective Cervical Lymphatic Drainage
por: Kim, Young Kook, et al.
Publicado: (2017)

Hypoxia may be a determinative factor in COVID-19 progression
por: Grieb, Pawel, et al.
Publicado: (2021)

Choosing The Right Animal Model for Renal Cancer Research()
por: Sobczuk, Paweł, et al.
Publicado: (2020)

Mirtogenol(®) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
por: Steigerwalt, Robert D, et al.
Publicado: (2010)

Magnetic resonance in studies of glaucoma
por: Fiedorowicz, Michał, et al.
Publicado: (2011)

Effect of latanoprost on intraocular pressure, visual acuity and C-reactive protein
por: Hou, Ping, et al.
Publicado: (2020)

A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects
por: Matloka, Mikolaj, et al.
Publicado: (2022)

Additive Effect of Brinzolamide on Diurnal Changes in Intraocular Pressure in Latanoprost-treated Eyes
por: Abe, Keitetsu, et al.
Publicado: (2008)

Effects of Topical Latanoprost on Intraocular Pressure and Myopia Progression in Young Guinea Pigs
por: El-Nimri, Nevin W., et al.
Publicado: (2018)

Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure–Lowering Effects of Latanoprost
por: Roddy, Gavin W., et al.
Publicado: (2017)

Citicoline for Supporting Memory in Aging Humans
por: Świątkiewicz, Maciej, et al.
Publicado: (2023)

Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination
por: Sellem, Eric, et al.
Publicado: (2010)

Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes
por: Fiedorowicz, Michal, et al.
Publicado: (2019)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Özkurt, Yelda Buyru, et al.
Publicado: (2009)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Nakamura, Yoshimi, et al.
Publicado: (2009)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
por: Russo, Andrea, et al.
Publicado: (2008)

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
por: Wang, Yulong, et al.
Publicado: (2020)

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects
por: Shim, Seong Hee, et al.
Publicado: (2014)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
por: Ikeda, Yoko, et al.
Publicado: (2016)

Effect of a Topical Combination of Latanoprost and Pranoprofen on Intraocular Pressure and the Ocular Surface in Open-Angle Glaucoma Patients
por: Zhu, Simin, et al.
Publicado: (2018)

Influence of Trace Elements on Neurodegenerative Diseases of The Eye—The Glaucoma Model
por: Kamińska, Agnieszka, et al.
Publicado: (2021)

Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review
por: Białczyk, Aleksandra, et al.
Publicado: (2023)

Effect on Intraocular Pressure of Switching from Latanoprost and Travoprost Monotherapy to Timolol Fixed Combinations in Patients with Normal-Tension Glaucoma
por: Igarashi, Ryoko, et al.
Publicado: (2014)

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
por: Ishikawa, Makoto, et al.
Publicado: (2009)

Effect of benzalkonium chloride–free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study
por: Lopes, Joao F., et al.
Publicado: (2015)

Stanniocalcin-1 (STC-1), a downstream effector molecule in latanoprost signaling, acts independent of the FP receptor for intraocular pressure reduction
por: Roddy, Gavin W., et al.
Publicado: (2020)

Molecular Imaging of Human Skeletal Myoblasts (huSKM) in Mouse Post-Infarction Myocardium
por: Fiedorowicz, Katarzyna, et al.
Publicado: (2021)

Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment
por: Rejdak, Konrad, et al.
Publicado: (2020)

Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early Intervention
por: Rejdak, Konrad, et al.
Publicado: (2022)

An Online Questionnaire-Based Survey of 1076 Individuals in Poland to Identify the Prevalence of Ophthalmic Symptoms in Autumn 2022
por: Kamińska, Agnieszka, et al.
Publicado: (2023)

Latanoprost-Loaded Nanotransfersomes Designed for Scalp Administration Enhance Keratinocytes Proliferation
por: Pena-Rodríguez, Eloy, et al.
Publicado: (2022)

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
por: Takemoto, Daisuke, et al.
Publicado: (2017)

Cataract Surgery to Lower Intraocular Pressure
por: Berdahl, John P.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_g345m4o38nff1msq7geg9qsr2h